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Abstract 
Little is known about engagement and retention in care of people diagnosed with chronic 
hepatitis C (HCV) in England. Establishing a cascade of care informs targeted interventions 
for improving case-finding, referral, treatment uptake and retention in care. Using data from 
the Sentinel Surveillance of Blood Borne Virus testing (SSBBV) between 2005-2014 we 
investigate the continuum of care of those tested for HCV in England. 
Persons ≥1 years old, with an anti-HCV test and subsequent RNA tests between 2005-2014 
reported to SSBBV were collated. We describe the cascade of care, as the patient pathway 
from a diagnostic test, referral into care, treatment, and patient outcomes.  
Between 2005-2014, 2,390,507 samples were tested for anti-HCV, corresponding to 
1,766,515 persons. 53,038 persons (35,190 men and 17,165 women) anti-HCV positive were 
newly reported to SSBBV. An RNA test, was conducted on 77.0% persons anti-HCV positive, 
72.3% of whom were viraemic (RNA positive) during this time period, 21.4% had evidence of 
treatment, and 3130 49.5% had evidence of a sustained virological response (SVR). In 
multivariable models confirmation of viraemia by RNA test varied by age and region/test 
setting; evidence of treatment varied by age, year of test and region/test setting; and SVR 
varied by age, year of test and region/setting of test. In conclusion,  
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Our findings provide HCV cascade of care estimates prior to the introduction of direct acting 
antivirals. These findings provide important baseline cascade estimates to benchmark 
progress towards elimination of HCV as a major public health threat. 
Key words:  
Barriers, Cascade, DAA HCV, SVR, Treatment 
 
Introduction 
An estimated 160,000 persons (0.4% of the population) in England are infected with 
hepatitis C virus (HCV) (1), a leading cause of liver disease worldwide. Over 85% of those 
diagnosed with HCV in England acquired their infection through injecting drug use (2). Both 
the incidence and prevalence of HCV infection, as well as associated morbidity and mortality 
are influenced by changes in treatment innovations, healthcare policy and delivery of 
services, socio-demographic factors and risk behaviours. Historically, the diagnosis, referral, 
treatment, and care of persons infected with HCV has been challenging due to the difficulty 
of health worker and patient engagement, with HCV disproportionately affecting persons 
from socially excluded groups [people who inject drugs (PWID), prison inmates, migrants] 
who generally have poorer health care access and outcomes (3).  
The previous standard of care, involving complex, poorly tolerated and long periods of 
treatment with ribavirin and pegylated interferon, provided a challenge to optimal 
treatment initiation and retention in care.  Improvements to care and health outcomes are, 
however, expected through the introduction of the new direct acting antiviral (DAA) 
treatments, which are more efficacious, of shorter treatment duration and have a better 
side effect profile than the previous treatment options. The timely use of the DAAs is 
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expected to lead to individual health benefits and to a reduction in the pool of infectious 
people, who are the source of onward transmission. Several modelling studies have shown 
that increased HCV treatment among PWID will reduce prevalence and onward transmission 
(4-8), especially when combined with opioid substitution therapy and high coverage of 
needle and syringe programmes (7). Modelling predicts that rapid scale up of HCV 
treatment in those with moderate to severe liver disease will curtail morbidity and mortality 
from end stage liver disease (9, 10), but to make a substantial impact on transmission, 
treatment of mild disease is also required (11). In the era of the new DAAs it is important, 
therefore, to have a baseline measure of the previous standard of care against which to 
assess the impact of treatment strategies with DAAs, and highlight where gaps in the patient 
pathway persist. 
In England little is known about engagement and retention in care, with modelling of 
pharmacy dispensing data for ribavirin and pegylated interferon between 2006 and 2011 
suggesting that only 3% of chronically infected persons were on treatment (10, 12). A study 
in Nottingham identified that less than half of diagnosed persons between 2001 and 2002 
were referred to care, with only 10% of patients being treated (13). A repeat pathway audit 
following improvements, by the same group, for patients diagnosed between 2010 and 
2011 showed an improvement in the referral rate to 80%, with 37% of patients receiving 
treatment (14). However, this local audit is likely to represent the best-case scenario of the 
cascade of care for patients, the pathway from a person’s diagnostic test, to care, 
treatment, and outcome, having been undertaken in an area with well-established clinical 
pathways and networks; it may therefore not be representative of the national picture.  
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Establishing a nationally representative cascade of care for HCV infected patients is critical 
for identifying where and which groups drop out of the care pathway to inform targeted 
interventions to improve case-finding, referral, treatment uptake and retention in care. In 
the absence of large and costly patient registries and cohorts, Sentinel Surveillance of Blood-
Borne Virus (SSBBV) testing can be used to indirectly estimate the proportion of individuals 
in each step of the care pathway.  
Using data collected by the SSBBV between 2005 and 2014, we investigated the care and 
management of those tested for HCV in England. In this paper, we describe differences in 
testing, confirmation of current infection, treatment initiation, and treatment outcome by 
patient demographic characteristics, year of testing, geographical region of testing and 
setting or specialty of diagnosis.  
 
Methods 
SSBBV is a unique surveillance system that captures all blood-borne virus tests regardless of 
the result for tests conducted at any one of 23 sentinel laboratories across England. 
Participating laboratories are estimated to cover approximately 65% of the English 
population for primary and reference HCV testing and are broadly representative of most 
laboratories providing HCV testing.  Data collection methods for SSBBV have been described 
previously (15). In summary, demographic and testing data for all individuals tested for 
hepatitis C-specific antibody  (anti-HCV), indicative of current or past infection (“ever 
infected”) and HCV-RNA (indicative of viraemia, i.e. current infection) are extracted from 
participating laboratory information systems. Individuals were de-duplicated, and test 
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results for each individual were linked over time using a combination of soundex code (a 
coding based on the person’s surname), first initial, date of birth and NHS number.  
Results from all persons ≥1 year old, with an anti-HCV test between 2005 and 2014 were 
collated with subsequent HCV-RNA tests where available. Persons aged <1 year were 
excluded due to the possibility of false-positive results from maternal antibodies, as were 
persons testing in renal services and all reference laboratories as these tests are unlikely to 
reflect normal testing practises. Persons with an RNA test prior to the first reported anti-
HCV result within SSBBV testing were also excluded as this was assumed to be evidence of 
previous HCV diagnosis outside of the SSBBV laboratory network. 
We describe the cascade of care as the patient pathway from the first anti-HCV test, referral 
into care, treatment, and patient outcomes. All persons had at least one year of follow-up 
following an initial anti-HCV test. The cascade of care was described for persons diagnosed 
anti-HCV positive by sex, age, source of anti-HCV test, and region of anti-HCV test.  
The following patient pathway was described: the number of persons tested for anti-HCV, 
and the number anti-HCV positive; for the anti-HCV positive patients, the number for whom 
an RNA test was conducted. The setting of a person’s anti-HCV test was grouped into one of 
10 clinical specialities based on the requesting department reported by the laboratory: 
general practitioner, community drug services, sexual health services (including HIV 
medicine), prisons, occupational health, antenatal and maternity services, accident and 
emergency department, liver specific services, general medicine, and other. General 
practice, emergency departments, community drug services, and prisons were categorised 
as primary care specialties; the rest, as secondary care. 
Treatment Algorithm 
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Evidence of treatment was derived using an algorithm where four or more sequential HCV-
RNA test results within a 390 day period of an initial positive RNA result was considered 
suggestive of monitoring during treatment with the standard of care (ribavirin and 
pegylated interferon based regimens) (15). Persons with a final negative HCV-RNA test 
result within the 390-day period were considered to have responded to therapy, and to 
have achieved a sustained virological response (SVR) (16). The algorithm was validated using a 
clinical cohort database in Nottingham, the algorithm results were found to have high sensitivity, 
specificity, PPV, NVP and inter-rater agreement. 
 
Treatment uptake was estimated for all persons with a positive HCV-RNA regardless of when 
the test was conducted following a positive anti-HCV result. Among those for whom there 
was evidence of treatment initiation, the proportion with SVR was estimated. 
 Statistical Analysis 
The cascade of care among those newly testing positive for anti-HCV was examined using 
descriptive analysis. Proportions were compared using the X2 test. Three multivariable 
models identified factors associated with having an RNA test following a positive anti-HCV 
test result, initiating treatment following a positive RNA result, and achieving SVR following 
treatment initiation, adjusting for year of diagnosis, age, sex, region and setting of diagnosis. 
An interaction between region and speciality of test was found to be significant (p<0.001) 
for both variables, and thus we re-categorised these two variables to create a new variable 
(London Primary Care, London Secondary Care, Outside London Primary Care, and Outside 
London Secondary Care). Statistical analyses were performed using STATA version 10 (Stata 
Corp., College Station, TX, USA).  
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The research presented as part of the present study was undertaken within the National 
Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Blood Borne 
and Sexually Transmitted Infections at University College London. 
 
Results 
Of the 2,390,507 samples, corresponding to 1,766,515 persons, tested for anti-HCV between 
2005 and 2014, 118,308 tests (5.0%), and 70,674 persons (4.0%) were found to be anti-HCV 
positive. London had the highest number of persons presenting for a HCV test (538,253), 
and by service type general practice had the highest number of persons tested (468,481). In 
contrast, the highest proportion of positive tests was in the North West (5.9%, 
19260/325,697), and among persons attending drug services (26.9%, 10,328/38,431), 
followed by prisons (17.4%, 6284/36,087). 
Among patients with a positive anti-HCV result (70,674), 66,716 had their first anti-HCV 
positive result between 2005 and 2014; 13,678 of these patients were excluded from 
further analysis as there was an RNA test reported to SSBBV prior to the first anti-HCV 
result.  Table 1 shows the characteristics of those tested and the remaining 53,038 persons 
(35,190 men and 17,165 women) newly anti-HCV positive within SSBBV. The median age at 
anti-HCV diagnosis was 39 years (interquartile range [IQR]: 31-47), with males representing 
67.2% of new anti-HCV positive persons, and 54.3% of persons were diagnosed anti-HCV 
positive in primary care settings. By source of referral, 28.2% were tested in general 
practice, 14.8% within community drug services, 13.0% in sexual health clinics including HIV 
services, 12.1% in general medical departments, 10.8% in other services, 9.7% in prisons, 
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5.4% in liver specific services, 3.5% through antenatal and maternity services, 1.5% in 
emergency departments, and 0.93% through occupational health. 
An RNA test, to determine whether a person had a current HCV infection, was conducted on 
40,856 (77.0%) anti-HCV positive patients; of these, 29,557 (72.3%) were HCV RNA positive; 
6326 (21.4%) of those known HCV RNA positive patients had evidence of treatment, of 
whom 3130 (49.5%) were estimated to have achieved an SVR. Overall, of all 53,038 newly 
anti-HCV positive persons, 6326 (11.9%) had evidence of treatment, and 3130 (5.9%) had 
evidence of a SVR. Figure 1 shows a simulated cascade of care for all persons chronically 
infected within England using these distributions. 
Among persons with an RNA test (40,856), for 26,537 (65%), the test was performed within 
seven days of the anti-HCV result (which indicates “reflex testing” of the original anti-HCV 
positive serum sample). A previous negative anti-HCV result was available for 3354 (6.3%) of 
anti-HCV positive persons, with the highest proportions of persons with a previous negative 
test among persons diagnosed in sexual health services (9.8%; 673/6889) or antenatal and 
maternity services (7.1%; 132/1854). 
Table 2a-c show unadjusted and adjusted associations between setting of test and 
demographic factors and whether an RNA test was conducted (2a), evidence of HCV 
treatment (2b), and evidence of SVR  (2c).  
In adjusted models region and setting of anti-HCV test remained associated with an RNA 
test following an anti-HCV positive result. Compared to persons testing in primary care 
settings in London, persons testing in secondary care settings in London were more likely to 
have had a subsequent RNA test [Odds Ratio (OR): 1.11 (95% confidence interval: 1.02-
1.20)], persons testing in primary care settings outside London were also more likely 
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[OR=1.21 (1.13-1.30)] whereas persons testing in secondary care services outside London 
were less likely to have had an RNA test [OR=0.75 (0.70-0.80)]. Furthermore, an RNA test 
was more likely for among those testing between 2008 and 2010 [OR=1.18 (1.11-1.24)] and 
between 2011 and 2014 [OR=1.12 (1.07-1.18)] when compared to 2005 and 2007. Finally, 
persons aged 50 years and over were less likely to have an RNA test [OR=0.92 (0.87-0.98)] 
compared with persons aged 30-39 years. 
In a multivariable model investigating predictors for treatment, region and setting of anti-
HCV test remained an independent predictor for evidence of treatment. Compared to 
persons testing in primary care settings in London, persons testing in secondary care 
settings in London and secondary care settings outside London were more likely to have 
evidence of treatment [OR=1.15 (1.03-1.29) and OR=1.14 (1.03-1.26), respectively]. 
Furthermore, evidence of treatment was more likely between 2008 and 2010 [OR=1.19 
(1.11-1.28)], and less likely between 2011 and 2014 [OR=o.76 (0.71-0.82)] when compared 
to years between 2005 and 2007 (table 1b) and more likely for all age groups when 
compared with persons aged 30-39 years [<15 years OR=2.73 (1.74-4.28) 15-29 years 
OR=1.11 (1.02-1.21), 40-49 years OR=1.38 (1.28-1.48), and ≥50 years OR=1.45 (1.34-1.57)]. 
Finally, in a multivariable model investigating evidence of SVR among persons treated, 
region and setting of anti-HCV test remained an independent predictor for evidence of SVR. 
Compared to persons testing in primary care settings in London, persons were more likely to 
have evidence of SVR outside of London regardless of setting [Outside London Primary Care 
OR=1.58 (1.34-1.87), and Outside London Secondary Care OR=1.50 (1.26-1.79)], and less 
likely in London secondary care [OR=0.74 (0.60-0.91)]. Evidence of SVR was less likely for 
persons aged 50 years and over when compared to those 30-39 years [OR= 0.76 (0.66-0.88)] 
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and more likely among persons diagnosed between 2008 and 2010 and between 2011 and 
2014 when compared to those diagnosed between 2005 and 2007 [OR=1.13 (1.00-1.27)] 
and OR=2.05 (1.80-2.33), respectively], (table 2c). 
 
Discussion 
Our analysis demonstrates that in the pre-DAA era, confirmation of a current HCV infection 
occurred in 77% of persons positive for anti-HCV, with a low uptake of treatment of 11.9%, 
and attainment of SVR 5.9% overall. If restricting the cascade to those who were RNA 
positive following an anti-HCV positive result, around a fifth had evidence of treatment and 
half of those were estimated to have been cured.  
Confirmation of current infection (viraemia) following a positive anti-HCV result is a critical 
first step in the cascade that triggers referral for and consideration of treatment. Among our 
population 65% of patients had had a test where the timing of the RNA test suggested that 
the same sample as for anti-HCV testing was used. Alternative pathways result in the 
antibody and RNA tests being conducted on separate samples requiring patients to re-
attend for a blood test, increasing the likelihood of loss to follow up. To counter this, NICE 
recommend that RNA testing be conducted on the same sample, referred to as “reflex 
testing” (17); this approach has been shown to reduce referral and testing costs, with a 
faster treatment initiation following a reflex test (18). 
Progression through the cascade varied considerably by patient demographics, setting, 
geography and year of diagnosis. Our data indicate that the distribution of positive anti-HCV 
results is consistent with populations disproportionately affected by HCV, with a higher 
proportion of men and those testing at community drug clinics and within prisons positive 
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for HCV. However, although positivity rates for anti-HCV and RNA were highest in those 
testing in community drug services and prisons, treatment coverage was the lowest at 6.6% 
and 5.9% respectively, compared with general practice where 17.7% of those with a positive 
RNA result being on treatment. Similarly, attainment of SVR was highest in general practice 
and secondary care services and lowest among persons initially presenting in drug services 
and prisons. These findings are likely a function of transient and mobile populations, access 
to care pathways, referral practice, local policy and/or clinician dependent offer of HCV 
therapy as well as uptake and compliance in the patient population. These disparities are 
similar to those observed in a two year retrospective cohort in Nottingham, where 
treatment initiation was highest in those diagnosed through general practice (43%), 
followed by secondary care (39%), drug services (32%), and then prisons (26%) (14). These 
cascade data reinforce well-articulated recommendations that community-based and 
patient-focused treatment delivery, including in prisons and drug services, are needed to 
reduce disengagement particularly among socially excluded groups (19, 20).  
Our findings provide baseline cascade of care estimates as new regimens based on DAAs are 
being introduced into England. The low overall treatment rate of 11.9% is consistent with 
those published for the USA, Canada, and Australia, with these published rates ranging from 
1.1%-25.6% (21-27). Those studies identified a number of factors associated with treatment 
initiation, with older age (21-23), current drug and alcohol use (21, 23, 26), and 
comorbidities (21, 23, 26) being associated with a reduced likelihood of treatment. In 
addition, patients reported deferring treatment until the availability of better therapies, 
because of treatment related perceptions, ability to comply, and concerns with side effects 
(24, 28).  
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In our data, the lower rates of treatment in recent years compared to 2007-2011 could 
reflect this deferral of treatment (whether clinician or patient driven) in anticipation of 
introduction of the DAA in 2014 /2015. The association between age and treatment uptake 
with under 15 and over 50 year olds having higher treatment coverage also likely reflect 
clinical prioritisation of the young to prevent liver chronic liver disease, and of older persons 
to curtail progression of liver disease. Conversely higher levels of attaining SVR in patients 
diagnosed in 2011-2014 may reflect more effective drug combinations and compassionate 
use of DAA (through the NHSE expanded access programme) in patient groups with 
decompensated cirrhosis /per-transplantation, while lower SVR attainment in older persons 
is expected as older age is associated with advanced disease stage and other co-morbidities 
which lower success of treatment. 
There were also wide variations in the different components of the cascade between 
geographic regions. For example, RNA testing following a positive HCV result ranged from 69 
to 80%; treatment initiation following a positive RNA test ranged from 7-20%; and SVR rates 
ranged from 2-13%. Although the reasons for these differences are multifactorial and likely 
reflect current and historical differences in the affected population structure, case mix, 
clinical networks, patient pathways and commissioning, and so are not necessarily directly 
comparable or simple to disentangle, regions should be aware of these disparities so they 
can reflect on where improvements could be made in their own models and adopt good 
practice from elsewhere. 
The recent national roll out of DAAs through the NHS, which are injection-free, easier to 
tolerate, and of shorter treatment duration is likely to transform the treatment landscape 
and   increase treatment uptake and completion among those chronically infected with HCV 
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– thus potentially narrowing a gap in the cascade.  However, inequalities in access to and 
outcome of treatment among socially excluded groups who have high rates of infection such 
as prisoners and PWID, as highlighted in this study, may persist and even widen with new 
DAAs if prevention and treatment services are not commissioned or delivered following an 
equitable approach. Future analysis of SSBBV data will enable persistent gaps to be 
identified and acted upon in the era of DAAs.  
Our study is limited by the fact that initial and follow-up testing for HCV may have occurred 
outside the 23 sentinel surveillance laboratories if patients moved location, thereby 
resulting in an under-estimate of upstream (e.g. where initial anti-HCV test was not found) 
and downstream activities (e.g. RNA testing for monitoring treatment not found) within the 
cascade.  Additionally, data on dried blood spot (DBS) testing which is being increasingly 
used in prison and community drug services, is most frequently tested in commercial 
laboratories and not captured by SSBBV, preventing follow up of individuals tested by DBS 
which is necessary for cascade of care estimations.  
This study provides important cascade estimates to benchmark progress towards 
elimination of HCV as a major public health threat, providing a baseline cascade of care for 
the pre-DAA period. These data will enable persistent barriers to be identified, as well as 
inequities in performance across geographical regions. The cascade of care contributes to 
the evaluation of clinical and public health HCV control strategies, which may inform the 
allocation of resource for health service planning. Furthermore, understanding and 
addressing patient and structural factors that influence engagement in the patient care 
pathway will impact the overall goal to reduce HCV transmission and HCV-associated 
cirrhosis, cancer and death. Collective and concerted efforts are needed to improve the 
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cascade of care for HCV within England, and to realise the population benefits from 
prevention and treatment interventions.  
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Table 1: Distribution of persons through the care cascade following a positive anti-HCV 
result, reported to sentinel surveillance 2005-2014. 
 
Anti-HCV 
tested 
Anti-HCV 
Positive * 
Had an RNA test Ever RNA positive 
Evidence of 
treatment 
Evidence of 
SVR 
 
n n % n % n % n % n % 
Total 1,766,515 53038 3.0 40856 77.0 29557 55.7 6326 11.9 3130 5.9 
Sex  
 
 
        
Male 926,534 35,190 3.8 27,313 75.8 20,701 58.8 4,479 12.7 2,180 6.2 
Female 807,015 17,165 2.1 13,156 65.2 8,580 50.0 1,842 10.7 947 5.5 
Not Reported 32,966 683 2.1 387 71.3 276 40.4 5 0.7 3 0.4 
Age Group  
 
 
        
<15 26,802 189 0.7 130 65.4 85 45.0 32 16.9 18 9.5 
15-29 517,654 9,891 1.9 7,593 69.7 5,294 53.5 1,061 10.7 561 5.7 
30-39 463,382 17,428 3.8 13,565 72.7 9,863 56.6 1,813 10.4 909 5.2 
40-49 300,534 14,583 4.9 11,398 72.7 8,284 56.8 1,961 13.4 981 6.7 
≥50 472,811 10,583 2.2 8,032 73.9 5,935 56.1 1,458 13.8 661 6.2 
Not Reported 9161 364 4.0 138 69.6 96 26.4 1 0.3 
 
0.0 
Source of referral  
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Emergency Department 21,871 799 3.7 604 73.7 445 55.7 63 7.9 23 2.9 
Drug Services 38,431 7,833 20.4 6,378 78.1 4,984 63.6 516 6.6 273 3.5 
General Practice 468,481 14,931 3.2 12,100 74.4 8,998 60.3 2,643 17.7 1,400 9.4 
Sexual Health  (including HIV) 335,436 6,889 2.1 4,974 63.7 3,166 46.0 489 7.1 149 2.2 
Occupational Health 132,703 494 0.4 358 39.4 141 28.5 23 4.7 9 1.8 
Prison 36,087 5,152 14.3 3,868 71.8 2,776 53.9 306 5.9 128 2.5 
Liver Services 71,182 2,846 4.0 2,486 76.5 1,902 66.8 545 19.1 294 
10.
3 
Maternity/Antenatal Care 177,201 1,854 1.0 1,303 59.6 777 41.9 205 11.1 119 6.4 
General Hospital 203,523 6,396 3.1 4,295 72.4 3,111 48.6 718 11.2 310 4.8 
Other 280,042 5,698 2.0 4,387 72.5 3,179 55.8 814 14.3 423 7.4 
Not reported 1558 146 9.4 103 75.7 78 53.4 4 2.7 2 1.4 
Region  
 
 
        
East Midlands 142,098 3,118 2.2 2,573 75.6 1,946 62.4 470 15.1 279 8.9 
East of England 78,083 1,842 2.4 1,111 75.9 843 45.8 232 12.6 164 8.9 
London 538,253 13,173 2.4 10,312 68.6 7,078 53.7 1,542 11.7 595 4.5 
North East 110,293 2,817 2.6 2,204 80.3 1,770 62.8 453 16.1 123 4.4 
North West 325,697 14,192 4.4 10,243 71.3 7,301 51.4 1,306 9.2 784 5.5 
South Central 42,867 993 2.3 743 75.2 559 56.3 66 6.6 49 4.9 
South East Coast 142,190 3,814 2.7 2,925 71.6 2,095 54.9 259 6.8 173 4.5 
South West 130,979 5,323 4.1 4,831 70.4 3,400 63.9 716 13.5 120 2.3 
West Midlands 73,219 2,022 2.8 1,247 76.1 949 46.9 147 7.3 75 3.7 
Yorkshire and the Humber 182,798 5,744 3.1 4,667 77.5 3,616 63.0 1,135 19.8 768 
13.
4 
Not Reported 38           
Year of anti-HCV test  
 
 
        
2005 104,618 4,930 4.7 3,566 75.9 2,705 54.9 542 11.0 255 5.2 
2006 111,710 5,565 5.0 4,190 72.9 3,055 54.9 648 11.6 271 4.9 
2007 129,383 5,590 4.3 4,273 71.1 3,039 54.4 755 13.5 320 5.7 
2008 160,030 5,807 3.6 4,452 69.9 3,113 53.6 800 13.8 337 5.8 
2009 174,503 5,572 3.2 4,417 69.2 3,058 54.9 803 14.4 318 5.7 
2010 171,689 5,155 3.0 4,078 70.1 2,859 55.5 690 13.4 384 7.4 
2011 178,437 5,177 2.9 4,181 71.8 3,004 58.0 667 12.9 391 7.6 
2012 201,962 5,101 2.5 3,923 74.5 2,921 57.3 545 10.7 326 6.4 
2013 241,903 4,988 2.1 3,899 74.2 2,893 58.0 501 10.0 311 6.2 
2014 292,280 5,153 1.8 3,877 75.1 2,910 56.5 375 7.3 217 4.2 
* 3958 persons were excluded as their first anti-HCV positive result known to SSBBV was prior to 2005, and 13,678 persons 
were excluded as there was an RNA test reported to SSBBV prior to the first anti-HCV result. 
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Figure 1: The cascade of care for persons with chronic HCV in England in the era of ribavirin and pegylated interferon treatment (Bars), and the proportion 
of persons who move to the next stage of the care pathway (squares), using the sentinel surveillance of blood borne virus testing database, 2005-2014. 
 
 
¥
 Derived using an algorithm where four or more sequential RNA test results within a 390 day period of an initial positive RNA result was considered to be monitoring during treatment with the 
standard of care in the study period which included ribavirin and pegylated interferon. 
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Table 2: Results from logistic regression analysis to identify factors associated with a. having an RNA 
test following a positive anti-HCV result, b. evidence of treatment among persons with a current 
infection (RNA positive), and c. evidence of achieving an SVR, reported to sentinel surveillance 2005-
2014.  
a. 
 Unadjusted Adjusted 
 OR 95% CI OR 95% CI 
Year of anti-HCV test       
2005 - 2007 1   1  
2008 - 2010 1.21 1.44-1.27  1.18 1.11-1.24 
2011 - 2014 1.18 1.12-1.24  1.12 1.07-1.18 
Age Group      
<15 0.66 0.48-0.92  0.74 0.54-1.03 
15-29 0.96 0.90-1.02  0.97 0.91-1.03 
30-39 1   1  
40-49 1.02 0.97-1.08  1.03 0.97-1.08 
≥50 0.89 0.84-0.94  0.92 0.87-0.98 
Sex      
Male 1   1  
Female 0.94 0.90-0.98  0.96 0.92-1.00 
Region / Source of Referral      
London Primary Care 1   1  
London Secondary Care 1.12 1.03-1.21  1.11 1.02-1.20 
Outside London Primary Care 1.22 1.40-1.31  1.21 1.13-1.30 
Outside London Secondary Care 0.74 0.69-0.79  0.75 0.70-0.80 
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b. 
 Univariate Multivariate 
 OR 95% CI OR 95% CI 
Year of anti-HCV test       
2005 - 2007 1   1  
2008 - 2010 1.21 0.13-1.29  1.19 1.11-1.28 
2011 - 2014 0.77 0.72-0.83  0.76 0.71-0.82 
Age Group      
<15 2.74 1.76-4.28  2.73 1.74-4.28 
15-29 1.11 1.02-1.21  1.11 1.02-1.21 
30-39 1  
 
1  
40-49 1.37 1.28-1.48  1.38 1.28-1.48 
≥50 1.43 1.33-1.55  1.45 1.34-1.57 
Sex      
Male 1   1  
Female 0.99 0.93-1.05  0.99 0.93-1.05 
Region / Source of Referral      
London Primary Care 1   1  
London Secondary Care 1.17 1.04-1.31  1.15 1.03-1.29 
Outside London Primary Care 1.01 0.92-1.11  1.07 0.97-1.17 
Outside London Secondary Care 1.14 1.03-1.26  1.14 1.03-1.26 
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c. 
 Univariate Multivariate 
 OR 95% CI OR 95% CI 
Year of anti-HCV test       
2005 - 2007 1   1  
2008 - 2010 1.08 0.96-1.22  1.13 1.00-1.27 
2011 - 2014 1.92 1.70-2.18  2.05 1.80-2.33 
Age Group      
<15 1.28 0.63-2.59  1.21 0.60-2.53 
15-29 1.12 0.96-1.30  1.09 0.92-1.25 
30-39 1   1  
40-49 1.00 0.88-1.14  0.99 0.87-1.13 
≥50 0.83 0.72-0.95  0.75 0.66-0.88 
Sex      
Male 1   1  
Female 1.12 1.00-1.25  1.09 0.97-1.22 
Region / Source of Referral      
London Primary Care 1  
 
1  
London Secondary Care 0.75 0.61-0.93  0.74 0.60-0.91 
Outside London Primary Care 1.60 1.36-1.90  1.58 1.34-1.87 
Outside London Secondary Care 1.44 1.21-1.72  1.94 1.26-1.97 
 
 
 
 
 
